+1 (704) 266-3234
+1 (704) 266-3234You are here :
Published on: Feb 2021 | From USD $2900 | Published By: KONCEPT ANALYTICS | Number Of Pages: 93
The global hepatitis B virus (HBV) market is expected to reach US$35.63 billion in 2030, increasing at a CAGR of 29.41%, for the period of 2021-2030. The factors such as growth of pharmaceutical industry, increase in ageing population, upsurge in healthcare expenditure, urbanization leading to better monitoring and screening procedures and increase in liver cancer and cirrhosis deaths due to HBV would drive the growth of the market. However, the market growth would be challenged by rigid competition, management challenges, lack of diagnostic facilities and high cost of medical care and legal regulations. A few notable trends may include growth in pharmaceutical research and development, collaboration, innovation and research, high demand for biomarker based tests, HBV treatments in development and government initiatives and public awareness.
The HBV market is fragmented in nature and the degree of fragmentation would accelerate during the forecast period. To make the most of the opportunities, market players are focusing more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Key players are investing significant amount of funds on the pharmaceutical research and development in order to expand the product portfolio of hepatitis B therapeutics, which is likely to help in the considerable growth of the global hepatitis b virus (HBV) market.
The fastest regional market is the U.S., due the presence of the well established healthcare infrastructure. With the increase in the prevalence of hepatitis B, the demand for treatment of the disease is becoming prominent. Therefore, some of the government and non-government organizations are taking the initiative to bring awareness about hepatitis B, which would help in the growth of the global HBV market in coming years.
Scope of the report:
The report provides a comprehensive analysis of the global Hepatitis B Virus (HBV) Market.
The major regional markets (the U.S., European Union and Japan) have been analyzed.
The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
The competitive landscape of the market, along with the company profiles of leading players (Johnson & Johnson, Merck & Co., Bristol-Myers Squibb, Gilead Sciences, Arrowhead Pharmaceuticals and Arbutus Pharma are also presented in detail.
Key Target Audience:
Hepatitis B Virus Therapeutics Manufacturers
Pharmaceuticals and Biopharmaceutical Firms
End Users (Hospitals and Research Institutes)
Investment Banks
Healthcare and Medical Consultants
Government Bodies & Regulating Authorities
1. Market Overview
1.1 HBV: Introduction
1.2 Causes of Hepatitis B
1.3 Symptoms of Hepatitis B
1.4 Test and Diagnosis of Hepatitis B
1.5 Risk of Hepatitis B
1.6 HBV Blood Tests
1.7 Chronic HBV Disease Phases
1.8 Current HBV Treatments
2. Impact of COVID-19
2.1 Growth in Government Spending on Healthcare
2.2 COVID-19 Antiviral Drugs Candidates
2.3 Chloroquine and COVID-19
3. Global HBV Market Analysis
3.1 Global HBV Market
3.2 Global HBV Market by Antiviral Drug Class
3.2.1 Global RNA Interference Antiviral Market Forecast by Value
3.2.2 Global Entry Inhibitor Antiviral Market Forecast by Value
3.2.3 Global Core Inhibitor Antiviral Market Forecast by Value
3.2.4 Global Antisense Antiviral Market Forecast by Value
3.2.5 Global HBsAg Inhibitors Antiviral Market Forecast by Value
4. Regional Market Analysis
4.1 The US
4.1.1 The US HBV Market Forecast by Value
4.1.2 The US Chronic HBV Patients Forecast by Volume
4.1.3 The US Diagnosed HBV Patients Forecast by Volume
4.1.4 The US Treated HBV Patients Forecast by Volume
4.2 European Union
4.2.1 European Union HBV Market Forecast by Value
4.2.2 European Union Chronic HBV Patients Forecast by Volume
4.2.3 European Union Diagnosed HBV Patients Forecast by Volume
4.2.4 European Union Treated HBV Patients Forecast by Volume
4.3 Japan
4.3.1 Japan HBV Market Forecast by Value
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Expansion of Pharmaceutical Industry
5.1.2 Increase in Ageing Population
5.1.3 Increasing Healthcare Expenditure
5.1.4 Urbanization leading to Better Monitoring and Screening Procedures
5.1.5 Increase in Liver Cancer and Cirrhosis Deaths due to HBV
5.2 Market Trends
5.2.1 Growth in Pharmaceutical Research and Development
5.2.2 Collaboration, Innovation and Research
5.2.3 High Demand for Biomarker Based Tests
5.2.4 HBV Treatments in Development
5.2.5 Government Initiatives and Public Awareness
5.3 Challenges
5.3.1 Rigid Competition
5.3.2 Management Challenges
5.3.3 Lack of Diagnostic Facilities and High cost of Medical Care
5.3.4 Legal Regulations
6. Competitive Landscape
6.1 Key Players Revenue Comparison
6.2 Key Players R&D Expenditure Comparison
6.3 Key Players Market Capitalization Comparison
6.4 Global HBV Therapies in Development by Company
6.5 Global Capsid Inhibitor Therapy in Development by Company
6.6 Global RNAi Gene Silencer Therapy in Development by Company
7. Company Profiles
7.1 Johnson & Johnson
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 Merck and Co.
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategies
7.3 Bristol-Myers Squibb
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategies
7.4 Gilead Sciences
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategies
7.5 Arrowhead Pharmaceuticals
7.5.1 Business Overview
7.5.2 Financial Overview
7.5.3 Business Strategies
7.6 Arbutus Pharma
7.6.1 Business Overview
7.6.2 Financial Overview
7.6.3 Business Strategies
List of Figures
CHB Treatment Timeline
Global Government Share on Health Spending (2019-2024)
Global HBV Market Forecast by Value (2021-2030)
Global RNA Interference Antiviral Market Forecast by Value (2021-2030)
Global Entry Inhibitor Antiviral Market Forecast by Value (2021-2030)
Global Core Inhibitor Antiviral Market Forecast by Value (2021-2030)
Global Antisense Antiviral Market Forecast by Value (2021-2030)
Global HBsAg Inhibitors Antiviral Market Forecast by Value (2021-2030)
The US HBV Market Forecast by Value (2021-2030)
The US Chronic HBV Patients by Volume (2021-2030)
The US Diagnosed HBV Patients Forecast by Volume (2021-2030)
The US Treated HBV Patients Forecast by Volume (2021-2030)
European Union HBV Market Forecast by Value (2021-2030)
European Union Chronic HBV Patients Forecast by Volume (2021-2030)
European Union Diagnosed HBV Patients Forecast by Volume (2021-2030)
European Union Treated HBV Patients Forecast by Volume (2021-2030)
Japan HBV Market Forecast by Value (2021-2030)
Global Total Prescription Drugs Sales (2020-2024)
Global Ageing Population Above 60+ (2021-2030)
Global Healthcare Expenditure (2016-2020)
Global Urban Population (2016-2020)
Global Pharmaceutical Research and Development Expenditures (2021-2030)
Johnson & Johnson Total Sales and Net Earnings (2015-2019)
Johnson & Johnson Total Sales by Segments (2019)
Johnson & Johnson Total Sales by Regions (2019)
Merck and Co. Sales and Net Income (2015-2019)
Merck and Co. Sales by Segments (2019)
Merck and Co. Sales by Regions (2019)
Bristol-Myers Squibb Total Revenue and Net Earnings (2015-2019)
Bristol-Myers Squibb Total Revenue by Operations (2019)
Bristol-Myers Squibb Total Revenue by Regions (2019)
Gilead Sciences Total Revenue and Net Income (2015-2019)
Gilead Sciences Total Revenue by Operations (2019)
Gilead Sciences Total Revenue by Regions (2019)
Arrowhead Pharmaceuticals Revenue and Net Income (Loss) (2016-2020)
Arbutus Revenue and Net Loss (2015-2019)
List of Tables
HBV Blood Tests and Indications
Chronic HBV Disease Phases
Key Players Revenue Comparison (2019/2020)
Key Players R&D Expenditure Comparison (2019/2020)
Key Players Market Capitalization Comparison (2021)
Global HBV Therapies in Development by Company
Global Capsid Inhibitor Therapy in Development by Company
Global RNAi Gene Silencer Therapy in Development by Company
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
In-depth database
Our Report’s database covers almost all topics of all regions over the Globe..
Recognised publishing sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales support.
Safe & Secure
Complete secure payment process.
: sales@marketintelligencedata.com
: 1137 waynewood dr,Waxhaw NC 28173 ,United States
: +1 (704) 266-3234
